PRINCETON, N.J.–(BUSINESS WIRE)–Oct. 15, 2024– UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced U.S. Food and Drug…Original Article
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
